849935-85-9

Usage

Uses

Used in Pharmaceutical Industry:
(3S,4R)-1-tert-butyl 3-ethyl 4-hydroxypyrrolidine-1,3-dicarboxylate is used as an intermediate in the preparation of various substituted fused quadracyclic compounds. These compounds are of interest due to their potential as inhibitors of MK2, a kinase enzyme involved in inflammatory and stress response pathways. By targeting MK2, these quadracyclic compounds may offer therapeutic benefits in treating conditions associated with excessive inflammation or cellular stress.
Additionally, the chiral nature and unique functional groups of (3S,4R)-1-tert-butyl 3-ethyl 4-hydroxypyrrolidine-1,3-dicarboxylate make it a valuable building block for the development of other pharmaceutical agents with specific biological activities. Its use in the synthesis of such compounds can lead to the discovery of new drugs with improved efficacy and selectivity.

InChI:InChI=1/C12H21NO5/c1-5-12(9(15)16)7-13(6-8(12)14)10(17)18-11(2,3)4/h8,14H,5-7H2,1-4H3,(H,15,16)/t8-,12-/m0/s1

Upstream product

• 146256-98-6 4-oxo-pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 108-05-4 vinyl acetate 
• 1523541-94-7 (trans)-1-tert-butyl 3-ethyl 4-hydroxypyrrolidine-1,3-dicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1378850-15-7 C₇H₁₃NO₃ 

Relevant academic research and scientific papers

TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The present disclosure relates to compounds which modulate the activity of Toll-like receptor (TLR) proteins, including agonists or activators, partial agonists, and antagonists. Of particular interest of compounds that modulate the activity of TLR2, as well as methods of using such compounds to treat cancer and other disorders associated with a TLR2 pathway.

FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF

Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

Synthesis, antimycobacterial and antibacterial activity of fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety

A series of novel fluoroquinolone derivatives containing an 3-alkoxyimino-4-(cyclopropylanimo)methylpyrrolidine moiety were designed, synthesized and evaluated for their biological activity. Our results revealed that 19b2 shows good activity against MTB H

METHOD FOR PREPARING 3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDINE COMPOUNDS

This invention relates to a method of preparing (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine, a key intermediate compound for the synthesis of certain inhibitor compounds, including the step of enzyme catalysed enantioselective esterification of an hydroxy group of an hydroxypyrrolidine. The invention further relates to a method for preparing (3S,4S)-3-hydroxy-4-hydroxymethylpyrrolidine, which is the enantiomer of (3R,4R)-3-hydroxy-4-hydroxymethylpyrrolidine.

Peptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production, and drugs containing these compounds

Arginine mimetic peptides according to Formula I of this application have a stimulating effect on bone formation and are useful for the treatment of bone metabolic disorders.

Amidinopyrroline derivatives, processes for their production and pharmaceutical agents containing these compounds

Compound of formula (I) are disclosed STR1 as well as optically active isomers or pharmacologically acceptable salts thereof. The compounds are useful active ingredients in pharmaceutical compositions, and methods of treating osteoporosis, inflammation or